Another first-in-human trial reported three recurrent GBM patients treated through 12 local infusions with CAR-T cells, autologous CD8+ CTLs targeting interleukin 13 receptor subunit alpha 2 (IL13Rα2). This evidence concerns the gene CD8A and glioblastoma.